GlucoTrack Inc (NASDAQ: GCTK) is a medical device company developing an implantable continuous glucose monitoring (CGM) system. The company has no disclosed commercial revenue as of the fiscal year ended December 31, 2025, operating as a pre-commercial stage device developer dependent on external financing to fund operations. GlucoTrack competes in the CGM market against Abbott Laboratories, DexCom, and Medtronic, which collectively account for substantially all worldwide CGM sales as of the 10-K filed March 30, 2026. The company is incorporated in Delaware and has faced repeated Nasdaq compliance issues, including minimum stockholders' equity deficiencies and bid price rule violations. GlucoTrack executed two reverse stock splits in fiscal year 2025, a 1-for-20 split effective February 3, 2025, and a 1-for-60 split effective June 13, 2025, reflecting sustained pressure on its capital structure. The company relies on equity offerings, convertible debt, and potential licensing or distribution arrangements to fund development activity.

Revenue model

GlucoTrack generates no disclosed commercial product revenue as of the fiscal year ended December 31, 2025. The company funds operations through equity offerings, promissory notes, and convertible promissory notes, as reflected on the consolidated balance sheets for December 31, 2025 and December 31, 2024 (10-K filed March 30, 2026).

Products and services

GlucoTrack is developing an implantable CGM device. The filing notes there is currently one implantable CGM on the market, positioning GlucoTrack's product as a development-stage entrant in that segment. No commercial product has been disclosed as launched as of the 10-K filed March 30, 2026.

Customers and end markets

The target end market is glucose monitoring for diabetes patients. No commercial customers or revenue-generating customer relationships are disclosed in the 10-K filed March 30, 2026.

Value-chain role

GlucoTrack occupies a device development and manufacturing role in the CGM value chain, subject to FDA premarket approval (PMA) requirements and clinical study completion before any commercial distribution. The company has an at-the-market sales agreement with Dawson James Securities, Inc., dated December 17, 2024, for capital raising.

Geographic exposure

GlucoTrack is incorporated in Delaware. The 10-K filed March 30, 2026 does not disclose specific geographic revenue breakdowns or commercial operating markets.

Competitors

Abbott Laboratories (FreeStyle Libre 3), DexCom (G7), Medtronic (Guardian 4 / MiniMed 780G)

Source: SEC 10-K, filed 2026-03-30

Industry: Surgical & Medical Instruments & Apparatus Peers: Check Cap Ltd Inspira Technologies Oxy BHN Ltd